- Home
- NVS
NVS
Novartis AG
as 11-20-2024 4:00pm EST
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 230.5B | IPO Year: | 1991 |
| Target Price: | $121.25 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 8.58 | EPS Growth: | 130.53 |
| 52 Week Low/High: | $92.35 - $120.92 | Next Earning Date: | 10-29-2024 |
| Revenue: | $49,940,000,000 | Revenue Growth: | 8.92% |
| Revenue Growth (this year): | 10.04% | Revenue Growth (next year): | 4.55% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 hours ago
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
GlobeNewswire
2 days ago
Novartis ranks first in 2024 Access to Medicine Index
Pharmaceutical Technology
2 days ago
Novartis strengthens radiopharma leadership with Ratio Therapeutics deal
BioPharma Dive
2 days ago
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
Zacks
3 days ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
MT Newswires
3 days ago
Novartis Pharma, Ratio Therapeutics Collaborate to Develop Cancer Treatment Candidate
PR Newswire
3 days ago
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
Morningstar Research
3 days ago
Analyst Report: Novartis AG
Compare NVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.